As shown in the following slide detailing the partnership terms: The company also reported promising clinical results for GUBamy, with Phase 1 Multiple Ascending Dose (MAD) Part A study showing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback